



OnKure Therapeutics to Participate in Upcoming Investor Conferences

November 4, 2025

BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences:

- A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this [link](#).
- A corporate presentation at the Stifel Healthcare Conference, in New York on November 12, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this [link](#).
- A fireside chat at the Evercore Healthcare Conference, in Miami on December 3, 2025, at 12:30 p.m. ET. A live audio webcast will be available through this [link](#).

Following the events, replays will be available on the OnKure website ([click here](#)) for 30 days.

About OnKure Therapeutics

OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3K α^{H1047R} inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic or pathologically activated PI3K α and has multiple programs designed to enable best-in-class targeting of this key disease creating gene.

For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.

Contact:

Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com